Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials
Long-acting injectable antiretroviral therapy (LA ART) may be an alternative for people living with HIV (PLHIV) with adherence challenges or who prefer not to take pills. Using in-depth interviews, this study sought to understand the experiences of PLHIV (n = 53) participating in Phase 3 LA ART tria...
Gespeichert in:
Veröffentlicht in: | AIDS and behavior 2020-12, Vol.24 (12), p.3473-3481 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3481 |
---|---|
container_issue | 12 |
container_start_page | 3473 |
container_title | AIDS and behavior |
container_volume | 24 |
creator | Mantsios, Andrea Murray, Miranda Karver, Tahilin S. Davis, Wendy Margolis, David Kumar, Princy Swindells, Susan Bredeek, U. Fritz García del Toro, Miguel Garcia Gasalla, Mercedes Rubio García, Rafael Antela, Antonio Hudson, Krischan Griffith, Sandy Kerrigan, Deanna |
description | Long-acting injectable antiretroviral therapy (LA ART) may be an alternative for people living with HIV (PLHIV) with adherence challenges or who prefer not to take pills. Using in-depth interviews, this study sought to understand the experiences of PLHIV (n = 53) participating in Phase 3 LA ART trials in the United States and Spain. The most salient consideration when contemplating LA ART was its clinical efficacy; many participants reported wanting to ensure that it worked as well as daily oral ART, including with less frequent dosing (every 8 versus 4 weeks). While injection side effects were often reported, most participants felt that regimen benefits outweighed such drawbacks. Participants described the main benefit of LA ART as the “freedom” it afforded both logistically and psychosocially, including through reduced HIV stigma. Findings highlight the importance of patient-provider communication related to weighing potential benefits and side effects and the continued need to address HIV stigma. |
doi_str_mv | 10.1007/s10461-020-02918-x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2404043363</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2471816323</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-f46e0ab2c3f0f1a49643e6ee25ba5b3fbe4907a3e7fdfd522fd3a5d4866665753</originalsourceid><addsrcrecordid>eNp9kc2O0zAUhSMEYn7gBVigK7FhE_Bv0rCrSmemUqWZRWFrOcl16yqxi-1C-048JO50AIkFtqx7JX_n3CudonhDyQdKSP0xUiIqWhJG8mvopDw8Ky6prHnJmRTPc08aUta0khfFVYxbQkhT1c3L4oIzkR0kvSx-zo2xne6OoF0PNwGx9-MneNDJokswP-ww5K7DCD9s2kDaIKyCdtEm6x2Y4Ef4rO1whPugB0gelt6ty2mXrFvDwm2xS7odEKYu2YAp-O_2BK42GPTueBKsAuoEd4uvYN2j_8y7hIcE3sDDRkcEnhmrh_iqeGFywddP9br4cjNfze7K5f3tYjZdlh2vZSqNqJDolnXcEEO1aCrBsUJkstWy5aZF0ZBac6xNb3rJmOm5lr2YVPnIWvLr4v3Zdxf8tz3GpEYbOxwG7dDvo2KC5Mt5xTP67h906_fB5e0yVdMJrTg7UexMdcHHGNCoXbCjDkdFiTplqc5ZqpylesxSHbLo7ZP1vh2x_yP5HV4G-BmI-cutMfyd_R_bX63Sq4w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471816323</pqid></control><display><type>article</type><title>Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials</title><source>SpringerNature Journals</source><source>Sociological Abstracts</source><creator>Mantsios, Andrea ; Murray, Miranda ; Karver, Tahilin S. ; Davis, Wendy ; Margolis, David ; Kumar, Princy ; Swindells, Susan ; Bredeek, U. Fritz ; García del Toro, Miguel ; Garcia Gasalla, Mercedes ; Rubio García, Rafael ; Antela, Antonio ; Hudson, Krischan ; Griffith, Sandy ; Kerrigan, Deanna</creator><creatorcontrib>Mantsios, Andrea ; Murray, Miranda ; Karver, Tahilin S. ; Davis, Wendy ; Margolis, David ; Kumar, Princy ; Swindells, Susan ; Bredeek, U. Fritz ; García del Toro, Miguel ; Garcia Gasalla, Mercedes ; Rubio García, Rafael ; Antela, Antonio ; Hudson, Krischan ; Griffith, Sandy ; Kerrigan, Deanna</creatorcontrib><description>Long-acting injectable antiretroviral therapy (LA ART) may be an alternative for people living with HIV (PLHIV) with adherence challenges or who prefer not to take pills. Using in-depth interviews, this study sought to understand the experiences of PLHIV (n = 53) participating in Phase 3 LA ART trials in the United States and Spain. The most salient consideration when contemplating LA ART was its clinical efficacy; many participants reported wanting to ensure that it worked as well as daily oral ART, including with less frequent dosing (every 8 versus 4 weeks). While injection side effects were often reported, most participants felt that regimen benefits outweighed such drawbacks. Participants described the main benefit of LA ART as the “freedom” it afforded both logistically and psychosocially, including through reduced HIV stigma. Findings highlight the importance of patient-provider communication related to weighing potential benefits and side effects and the continued need to address HIV stigma.</description><identifier>ISSN: 1090-7165</identifier><identifier>EISSN: 1573-3254</identifier><identifier>DOI: 10.1007/s10461-020-02918-x</identifier><identifier>PMID: 32410051</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Antiretroviral agents ; Antiretroviral drugs ; Antiretroviral therapy ; Clinical trials ; Drug therapy ; Freedoms ; Health Psychology ; HIV ; Human immunodeficiency virus ; Infectious Diseases ; Medicine ; Medicine & Public Health ; Original Paper ; Patients ; Prescription drugs ; Public Health ; Side effects ; Stigma</subject><ispartof>AIDS and behavior, 2020-12, Vol.24 (12), p.3473-3481</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-f46e0ab2c3f0f1a49643e6ee25ba5b3fbe4907a3e7fdfd522fd3a5d4866665753</citedby><cites>FETCH-LOGICAL-c375t-f46e0ab2c3f0f1a49643e6ee25ba5b3fbe4907a3e7fdfd522fd3a5d4866665753</cites><orcidid>0000-0002-3314-9173</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10461-020-02918-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10461-020-02918-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27344,27924,27925,33774,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32410051$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mantsios, Andrea</creatorcontrib><creatorcontrib>Murray, Miranda</creatorcontrib><creatorcontrib>Karver, Tahilin S.</creatorcontrib><creatorcontrib>Davis, Wendy</creatorcontrib><creatorcontrib>Margolis, David</creatorcontrib><creatorcontrib>Kumar, Princy</creatorcontrib><creatorcontrib>Swindells, Susan</creatorcontrib><creatorcontrib>Bredeek, U. Fritz</creatorcontrib><creatorcontrib>García del Toro, Miguel</creatorcontrib><creatorcontrib>Garcia Gasalla, Mercedes</creatorcontrib><creatorcontrib>Rubio García, Rafael</creatorcontrib><creatorcontrib>Antela, Antonio</creatorcontrib><creatorcontrib>Hudson, Krischan</creatorcontrib><creatorcontrib>Griffith, Sandy</creatorcontrib><creatorcontrib>Kerrigan, Deanna</creatorcontrib><title>Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials</title><title>AIDS and behavior</title><addtitle>AIDS Behav</addtitle><addtitle>AIDS Behav</addtitle><description>Long-acting injectable antiretroviral therapy (LA ART) may be an alternative for people living with HIV (PLHIV) with adherence challenges or who prefer not to take pills. Using in-depth interviews, this study sought to understand the experiences of PLHIV (n = 53) participating in Phase 3 LA ART trials in the United States and Spain. The most salient consideration when contemplating LA ART was its clinical efficacy; many participants reported wanting to ensure that it worked as well as daily oral ART, including with less frequent dosing (every 8 versus 4 weeks). While injection side effects were often reported, most participants felt that regimen benefits outweighed such drawbacks. Participants described the main benefit of LA ART as the “freedom” it afforded both logistically and psychosocially, including through reduced HIV stigma. Findings highlight the importance of patient-provider communication related to weighing potential benefits and side effects and the continued need to address HIV stigma.</description><subject>Antiretroviral agents</subject><subject>Antiretroviral drugs</subject><subject>Antiretroviral therapy</subject><subject>Clinical trials</subject><subject>Drug therapy</subject><subject>Freedoms</subject><subject>Health Psychology</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Infectious Diseases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Original Paper</subject><subject>Patients</subject><subject>Prescription drugs</subject><subject>Public Health</subject><subject>Side effects</subject><subject>Stigma</subject><issn>1090-7165</issn><issn>1573-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>BHHNA</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kc2O0zAUhSMEYn7gBVigK7FhE_Bv0rCrSmemUqWZRWFrOcl16yqxi-1C-048JO50AIkFtqx7JX_n3CudonhDyQdKSP0xUiIqWhJG8mvopDw8Ky6prHnJmRTPc08aUta0khfFVYxbQkhT1c3L4oIzkR0kvSx-zo2xne6OoF0PNwGx9-MneNDJokswP-ww5K7DCD9s2kDaIKyCdtEm6x2Y4Ef4rO1whPugB0gelt6ty2mXrFvDwm2xS7odEKYu2YAp-O_2BK42GPTueBKsAuoEd4uvYN2j_8y7hIcE3sDDRkcEnhmrh_iqeGFywddP9br4cjNfze7K5f3tYjZdlh2vZSqNqJDolnXcEEO1aCrBsUJkstWy5aZF0ZBac6xNb3rJmOm5lr2YVPnIWvLr4v3Zdxf8tz3GpEYbOxwG7dDvo2KC5Mt5xTP67h906_fB5e0yVdMJrTg7UexMdcHHGNCoXbCjDkdFiTplqc5ZqpylesxSHbLo7ZP1vh2x_yP5HV4G-BmI-cutMfyd_R_bX63Sq4w</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Mantsios, Andrea</creator><creator>Murray, Miranda</creator><creator>Karver, Tahilin S.</creator><creator>Davis, Wendy</creator><creator>Margolis, David</creator><creator>Kumar, Princy</creator><creator>Swindells, Susan</creator><creator>Bredeek, U. Fritz</creator><creator>García del Toro, Miguel</creator><creator>Garcia Gasalla, Mercedes</creator><creator>Rubio García, Rafael</creator><creator>Antela, Antonio</creator><creator>Hudson, Krischan</creator><creator>Griffith, Sandy</creator><creator>Kerrigan, Deanna</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7T2</scope><scope>7U3</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AM</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGRYB</scope><scope>BHHNA</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HEHIP</scope><scope>K7.</scope><scope>K9.</scope><scope>KB0</scope><scope>M0O</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2S</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3314-9173</orcidid></search><sort><creationdate>20201201</creationdate><title>Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials</title><author>Mantsios, Andrea ; Murray, Miranda ; Karver, Tahilin S. ; Davis, Wendy ; Margolis, David ; Kumar, Princy ; Swindells, Susan ; Bredeek, U. Fritz ; García del Toro, Miguel ; Garcia Gasalla, Mercedes ; Rubio García, Rafael ; Antela, Antonio ; Hudson, Krischan ; Griffith, Sandy ; Kerrigan, Deanna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-f46e0ab2c3f0f1a49643e6ee25ba5b3fbe4907a3e7fdfd522fd3a5d4866665753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antiretroviral agents</topic><topic>Antiretroviral drugs</topic><topic>Antiretroviral therapy</topic><topic>Clinical trials</topic><topic>Drug therapy</topic><topic>Freedoms</topic><topic>Health Psychology</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Infectious Diseases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Original Paper</topic><topic>Patients</topic><topic>Prescription drugs</topic><topic>Public Health</topic><topic>Side effects</topic><topic>Stigma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mantsios, Andrea</creatorcontrib><creatorcontrib>Murray, Miranda</creatorcontrib><creatorcontrib>Karver, Tahilin S.</creatorcontrib><creatorcontrib>Davis, Wendy</creatorcontrib><creatorcontrib>Margolis, David</creatorcontrib><creatorcontrib>Kumar, Princy</creatorcontrib><creatorcontrib>Swindells, Susan</creatorcontrib><creatorcontrib>Bredeek, U. Fritz</creatorcontrib><creatorcontrib>García del Toro, Miguel</creatorcontrib><creatorcontrib>Garcia Gasalla, Mercedes</creatorcontrib><creatorcontrib>Rubio García, Rafael</creatorcontrib><creatorcontrib>Antela, Antonio</creatorcontrib><creatorcontrib>Hudson, Krischan</creatorcontrib><creatorcontrib>Griffith, Sandy</creatorcontrib><creatorcontrib>Kerrigan, Deanna</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Social Services Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Criminal Justice Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Criminology Collection</collection><collection>Sociological Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Sociology Collection</collection><collection>ProQuest Criminal Justice (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Criminal Justice Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Sociology Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>AIDS and behavior</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mantsios, Andrea</au><au>Murray, Miranda</au><au>Karver, Tahilin S.</au><au>Davis, Wendy</au><au>Margolis, David</au><au>Kumar, Princy</au><au>Swindells, Susan</au><au>Bredeek, U. Fritz</au><au>García del Toro, Miguel</au><au>Garcia Gasalla, Mercedes</au><au>Rubio García, Rafael</au><au>Antela, Antonio</au><au>Hudson, Krischan</au><au>Griffith, Sandy</au><au>Kerrigan, Deanna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials</atitle><jtitle>AIDS and behavior</jtitle><stitle>AIDS Behav</stitle><addtitle>AIDS Behav</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>24</volume><issue>12</issue><spage>3473</spage><epage>3481</epage><pages>3473-3481</pages><issn>1090-7165</issn><eissn>1573-3254</eissn><abstract>Long-acting injectable antiretroviral therapy (LA ART) may be an alternative for people living with HIV (PLHIV) with adherence challenges or who prefer not to take pills. Using in-depth interviews, this study sought to understand the experiences of PLHIV (n = 53) participating in Phase 3 LA ART trials in the United States and Spain. The most salient consideration when contemplating LA ART was its clinical efficacy; many participants reported wanting to ensure that it worked as well as daily oral ART, including with less frequent dosing (every 8 versus 4 weeks). While injection side effects were often reported, most participants felt that regimen benefits outweighed such drawbacks. Participants described the main benefit of LA ART as the “freedom” it afforded both logistically and psychosocially, including through reduced HIV stigma. Findings highlight the importance of patient-provider communication related to weighing potential benefits and side effects and the continued need to address HIV stigma.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32410051</pmid><doi>10.1007/s10461-020-02918-x</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-3314-9173</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1090-7165 |
ispartof | AIDS and behavior, 2020-12, Vol.24 (12), p.3473-3481 |
issn | 1090-7165 1573-3254 |
language | eng |
recordid | cdi_proquest_miscellaneous_2404043363 |
source | SpringerNature Journals; Sociological Abstracts |
subjects | Antiretroviral agents Antiretroviral drugs Antiretroviral therapy Clinical trials Drug therapy Freedoms Health Psychology HIV Human immunodeficiency virus Infectious Diseases Medicine Medicine & Public Health Original Paper Patients Prescription drugs Public Health Side effects Stigma |
title | Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T03%3A59%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20Freedom:%20Patient%20Experiences%20with%20the%20Transition%20from%20Daily%20Oral%20to%20Long-Acting%20Injectable%20Antiretroviral%20Therapy%20to%20Treat%20HIV%20in%20the%20Context%20of%20Phase%203%20Trials&rft.jtitle=AIDS%20and%20behavior&rft.au=Mantsios,%20Andrea&rft.date=2020-12-01&rft.volume=24&rft.issue=12&rft.spage=3473&rft.epage=3481&rft.pages=3473-3481&rft.issn=1090-7165&rft.eissn=1573-3254&rft_id=info:doi/10.1007/s10461-020-02918-x&rft_dat=%3Cproquest_cross%3E2471816323%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2471816323&rft_id=info:pmid/32410051&rfr_iscdi=true |